Gastric inhibitory polypeptide (GIP) fits a LUCAS-FIBONACCI-midpoint with about 96.4% and thus corroborates Geier's equations and equilibrium concept; Tirzepatide fits with 87% to F9 - A first look by Stefan Geier et al.
Gastric inhibitory polypeptide (GIP) fits a LUCAS-FIBONACCI-number-midpoint with about 96.4% and thus corroborates Geier's equations and equilibrium concept; Tirzepatide fits with 87% to F9 - A first look
Gastric inhibitory polypeptide (GIP), also known as glucose-dependent insulinotropic polypeptide, is an inhibiting hormone of the secretin family of hormones. While it is a weak inhibitor of gastric acid secretion, its main role, being an incretin, is to stimulate insulin secretion.
GIP, along with glucagon-like peptide-1 (GLP-1), belongs to a class of molecules referred to as incretins, which stimulate insulin release on oral food intake.
Tirzepatide is an analog of the human GIP hormone with a C20 fatty diacid portion attached, that has been approved for treatment of diabetes in the US in May 2022.
The legth of the GIP peptide is 42 amino acids*.
This corroborates GEIER's equations and GEIER's programme** at an actual point of scientific, and clinical medical interest.
Tirzepatide has ~39 aa with a C20 fatty diacid portion attached***; a 87% fit to F9 for the peptide component. Hypothesis: Optimization to F9 or the F9-L8-midpoint to reduce adverse effects is putative possible.
For comparison:
Semaglutid: 32 aa; 98.4% fit to a 31.5 L7-F9-midpoint.****
Dulaglutid: 31 aa; 98.4% fit to a L7-F9-midpoint.*****
*Wikipedia, today: https://en.wikipedia.org/wiki/Gastric_inhibitory_polypeptide .
***Wikipedia, today: https://de.wikipedia.org/wiki/Tirzepatid .
****https://de.wikipedia.org/wiki/Semaglutid .
*****https://de.wikipedia.org/wiki/Dulaglutid .
...
Wikipedia, today:
| Description | English: Tirzepatide in 3 letter code |
| Date | |
| Source | Own work |
| Author | Benff |
Gerhart-Hauptmann-Strasse 6
83071 Haidholzen
Motivated by Katharina Geier (reported a putative adverse effect related necrotizing myositis, immune-mediated necrotizing myopathy IMNM, for Tirzepatide).
Additum 1:
Comparable considerations hold for Glucagon-like peptide-1 (GLP-1) with a length of 30 to 37 aa with the 9th FIBONACCI-number 34 at the center of the isoforms lengths (Wikipedia today: https://en.wikipedia.org/wiki/Glucagon-like_peptide-1):
Additum 2:
Selected fixed endpoints and sensitivity classifications
Endpoint | Observed | Exact F/L | Nearest F/L | Distance | m≤10 within 5% |
Genomic span | 7282 bp | No | 6765 (Fibonacci) | 7.10% | Yes |
Canonical mRNA length | 1434 nt | No | 1364 (Lucas) | 4.88% | Yes |
Total exon count | 6 exons | No | 5 (Fibonacci) | 16.67% | Yes |
Coding exon count | 4 exons | Yes | 4 (Lucas) | 0.00% | Yes |
Preproghrelin length | 117 aa | No | 123 (Lucas) | 5.13% | Yes |
Signal peptide length | 23 aa | No | 21 (Fibonacci) | 8.70% | Yes |
Ghrelin-28 length | 28 aa | No | 29 (Lucas) | 3.57% | Yes |
Obestatin candidate peptide length | 23 aa | No | 21 (Fibonacci) | 8.70% | Yes |
Acylated serine position in mature ghrelin | 3 position | Yes | 3 (Fibonacci and Lucas) | 0.00% | Yes |
Same acylated serine in precursor coordinates | 26 position | No | 29 (Lucas) | 11.54% | Yes |
Dominant octanoyl chain length | 8 carbons | Yes | 8 (Fibonacci) | 0.00% | Yes |
Observed decanoyl chain length | 10 carbons | No | 11 (Lucas) | 10.00% | Yes |
This substantially corroborates the above and GEIER's equations and GEIER's programme** at an actual point of scientific, and clinical medical interest.
#Wegovy #Ozempic #Rybelsus #Mounjaro
Kommentare
Kommentar veröffentlichen